Compare ABT & ITUB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABT | ITUB |
|---|---|---|
| Founded | 1888 | 1924 |
| Country | United States | Brazil |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.9B | 91.7B |
| IPO Year | 2006 | 2002 |
| Metric | ABT | ITUB |
|---|---|---|
| Price | $116.11 | $7.67 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 20 | 2 |
| Target Price | ★ $130.90 | $9.00 |
| AVG Volume (30 Days) | 5.8M | ★ 20.4M |
| Earning Date | 04-16-2026 | 05-05-2026 |
| Dividend Yield | 2.76% | ★ 6.12% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $44,328,000,000.00 | N/A |
| Revenue This Year | $10.75 | $46.47 |
| Revenue Next Year | $8.10 | $8.14 |
| P/E Ratio | $191.25 | ★ $12.60 |
| Revenue Growth | ★ 5.67 | N/A |
| 52 Week Low | $81.97 | $6.74 |
| 52 Week High | $137.49 | $9.60 |
| Indicator | ABT | ITUB |
|---|---|---|
| Relative Strength Index (RSI) | 75.26 | 41.46 |
| Support Level | $111.18 | $7.33 |
| Resistance Level | $116.82 | $7.51 |
| Average True Range (ATR) | 2.06 | 0.20 |
| MACD | 0.22 | -0.01 |
| Stochastic Oscillator | 89.30 | 28.10 |
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
Itaú Unibanco is the largest privately held bank in Brazil, the result of the 2008 merger between Banco Itaú and Unibanco. In addition to Brazil, the bank has significant operations in Chile, Colombia, Argentina, Uruguay, and Paraguay. Itaú's commercial and consumer loans account for 35% and 43% of the bank's total loans, respectively, while foreign loans account for 22% of its portfolio as of the end of 2025. The bank also operates the fifth-largest insurer in Brazil and is the second-largest asset manager in the country, giving it broad reach over the Brazilian financial system.